Trademarkia Logo

Canada

C$
Trademark Search in Canada
FEXUCLUE

View On IC.GC.CA

FEXUCLUE
REGISTERED

on 5 Jan 2024

Last Applicant/ Owned by

DAEWOONG PHARMACEUTICAL CO. LTD.

35-14, Jeyakgongdan 4-gil,Hyangnam-eup, Hwaseong-siGyeonggi-do

KR

Serial Number

2173276 filed on 19th Jan 2022

Registration Number

TMA1217552 registered on 5th Jan 2024

Registration expiry Date

19th Jan 2032

Correspondent Address

ERIN MCEWEN

NELLIGAN O'BRIEN PAYNE LLP 50 O'Connor StreetSuite 300Ottawa,

ONTARIO

CA

K1P6L2

FEXUCLUE

Trademark usage description

pharmaceutical agents affecting digestive organs for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointes Read More

Vienna Information

2 . 9 . 25

Other parts of the human body -- Notes: (a) Including human or animal sperm. (b) Not including heads, which will be placed in the appropriate sections of divisions 2.1, 2.3, 2.5 or 2.7.Autres parties du corps humain -- Notes: Y compris le sperme humain ou animal. (b) Non compris les têtes qui seront rangées dans les sections appropriées des divisions 2.1, 2.3, 2.5 ou 2.7.

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 8

Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.Lettres liées à un élément figuratif ou contenant un élément figuratif -- Note: Les lettres représentant un être humain ou une partie du corps humain, un animal ou une partie du corps d'un animal, un végétal, un corps céleste, un phénomène naturel ou un objet sont classées dans la division 27.3.

29 . 1 . 4

BlueBleu

29 . 1 . 3

GreenVert

29 . 1 . 1

Red, pink, orangeRouge, rose, orangé

29 . 1 . 2

Yellow, goldJaune, or

Classification Information

Class [005]
Pharmaceutical agents affecting digestive organs for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; medicines for treating intestinal disorders for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger- Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; medicines for the treatment of gastrointestinal diseases; medicines for human purposes for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; ethical medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection

Classification kind code

11

Mark Details

Serial Number

2173276

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 48
on 17th Aug 2023		Agent Changed
Submitted for opposition 256
on 17th Jan 2023		Notification of Possible Opposition Sent
Submitted for opposition 22
on 5th Oct 2022		Search Recorded
Submitted for opposition 20
on 5th Oct 2022		Examiner's First Report
Submitted for opposition 223
on 5th Oct 2022		Total Provisional Refusal
Submitted for opposition 257
on 17th Mar 2022		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 16th Mar 2022		Created
Submitted for opposition 31
on 16th Mar 2022		Formalized
Submitted for opposition 30
on 19th Jan 2022		Filed
Submitted for opposition 228
on 19th Jan 2022		International Registration